| Name | Title | Contact Details |
|---|
T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
XLTek is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quicksilver Scientific is a CLIA-certified laboratory that specializes in superior liposomal delivery systems, mercury testing and blood metal testing.
Esoterix Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Esoterix Inc. is based in Austin, TX. You can find more information on Esoterix Inc. at www.esoterix.com